Navigation Links
BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development
Date:10/21/2009

e in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(®) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. A number of POTELLIGENT(®) antibodies are being investigated in human clinical trials.

About BioWa, Inc.

BioWa is a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of AccretaMab(®) platform. AccretaMab(®) platform consists of POTELLIGENT(®) and COMPLEGENT(®) Technologies, creating a superior antibody molecule with enhanced ADCC and CDC activities. BioWa is offering POTELLIGENT(®) and COMPLEGENT(®) Technologies to partners under a license to maximize the value of these technologies. Together with Kyowa Hakko Kirin, BioWa is committed to promote ADCC/CDC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases. For more information about BioWa, visit its web site at http://www.biowa.com.

POTELLIGENT(®), COMPLEGENT(®), and AccretaMab(®) are the trademarks of Kyowa Hakko Kirin Co., Ltd. All rights are reserved.

About NKT Therapeutics

NKT Therapeutics, Inc. is a privately held biotechnology company focused on developing therapeutics based on unique immune cells called natural killer T (NKT) cells. The company's mission is to use its expertise to develop a pipeline of first-in-class NKT-based therapeutics to treat asthma, cancer, infectious diseases, autoimmune diseases, and dermatitis. For more information about NKTT, visit its web site at http://www.nktrx.com


'/>"/>
SOURCE BioWa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Morphotek(R), Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins
2. BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA
3. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
4. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
5. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
6. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
7. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
8. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
9. BioWa Announces Licensing of BioWas POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development
10. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
11. Professional Pricing Society Announces Educational Partnership with Vendavo -- "PPS Accepting Vendavo Pricing Knowledge Series Awards to Certified Pricing Professional Program"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... EVANSTON, Ill. , Dec. 19, 2014 ... to develop novel drugs for diseases of the central ... Ph.D., president and chief executive officer, will present at ... Dr. Riedel,s presentation will take place at 3:00 p.m. ... St. Francis in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... , SHANGHAI, Nov. ... Drug Administration (SFDA) has approved the,investigational new drug application (IND) ... treat diabetes. This IND,approval allows Biolaxy to initiate its first ... is a disorder characteristic of high blood glucose and poor,metabolism. ...
... ... by laboratories participating in or generating DNA records for the National DNA Index System. ... Madison, WI USA (PRWEB) -- ... laboratories participating in, or generating DNA records for, the National DNA Index System (NDIS). NDIS ...
... HTL , TORONTO, Nov. 24 /PRNewswire-FirstCall/ - Hamilton Thorne Ltd. (TSX-V: ... systems and instruments for the stem cell research and fertility clinic ... ended September 30, 2009. , , Q3 2009 ... compared with $1.43 million in Q3 2008, - ...
Cached Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research ... announced the addition of the "iPhone 5S ... Technology Report" report to their offering. ... Following the acquisition of AuthenTec in July 2012, ... iPhone 5S. It is currently the only device ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, ... publication of a study that pinpoints fine-scale differences in ... United States . Since immigrants first ... the United States has served as a ... illuminates how American history and the ongoing mixing of ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 323andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... the Electronic Nose, which has the potential to diagnose ... grant from Grand Challenges Canada and the Bill & ... testing of this ground-breaking technology. The ... able to detect TB immediately and non-invasively from the ...
... family of compounds that includes one of the most ... treatments. But the difficulty producing these complex molecules in ... family for further drug leads. Now, a group of ... step toward the goal of synthetically producing Taxol and ...
... name "Sleeping Beauty" has helped to unlock vital clues ... A study published today used the Sleeping Beauty transposon ... drive colorectal cancer, identifying many more than previously thought. ... human cancer, which provides strong evidence that they are ...
Cached Biology News:Creating an 'electronic nose' to sniff out tuberculosis from a patient's breath 2Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 2Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 3Scripps research team achieves critical step to opening elusive class of compounds to drug discovery 4Researchers discover genes involved in colorectal cancer 2
... complete enterprise microarray informatics platform for microarray data ... once and use it forever without paying ongoing ... Acuity has all the analysis tools you ... from quality control statistics and normalization, all the ...
... The RapidPlate 96/384 workstation offers precise 96 ... scalable format. Utilizing 100ul and 200ul disposable ... delivers excellent accuracy and precision across a ... rotary deck includes two positions that enable ...
... the ideal instrument for budget-conscious labs that want ... Get Applied Biosystems proven PCR performance ... space without sacrificing results. Enhance productivity ... You Can Afford The Applied Biosystems ...
... [6331] to Salmonella typhimurium The genus Salmonella ... genus is composed of Gram-negative bacilli that are ... antigens; the "H" or flagellar antigen (phase 1 ... of the LPS moiety) and the "Vi" or ...
Biology Products: